Performance Evaluation: Four Chemiluminescent SARS-Cov-2 Immunoassays and Rapid-Card Test in Mild Disease and Seroprevalence of SARS CoV-2 in Frontline Healthcare Workers
International Blood Research & Reviews,
Introduction: The COVID-19 pandemic raised a host of challenges to modern medicine. Key amongst these were in diagnostics, as most SARS-CoV-2 assays had been rapidly developed and released under emergency-use authorization with limited validation on clinical samples and secondly, an increased risk of COVID-19 infection to healthcare workers (HCW). There are limited inter-assay comparisons to detect SARS-CoV-2 antibodies in cases with milder symptoms of COVID-19, necessary to evaluate whether assays can detect SARS-CoV-2 antibodies in patients with mild infection.
Aim: Therefore this study aimed to evaluate the performance of four chemiluminescence immunoassays and a rapid immunochromatographic assay in 100 rRT-PCR diagnosed-recovered frontline HCW with milder COVID-19 disease and secondly to evaluate the seroprevalence of SARS-CoV-2 infection in the asymptomatic frontline HCW at a multispeciality hospital in Delhi, India.
Study Design: Serum and plasma samples were obtained from 100 rRT-PCR diagnosed-recovered frontline HCWs with mild disease working across the hospital, and performance of four common chemiluminescence immunoassays evaluated. Also samples of 505 asymptomatic, frontline HCWs working in hospital, who had not developed or shown any symptoms of COVID-19 infection to date was collected and the seroprevalence of infection was evaluated.
Place and Duration of the Study: A study was conducted at BLK Superspeciality Hospital, New Delhi from September to October 2020.
Methods: Four chemiluminescence immunoassays [Abbott SARS-CoV-2 IgG (Nucleocapsid), Roche Elecsys® Anti-SARS-CoV-2 Total (Nucleocapsid), Ortho-Clinical Diagnostics: VITROS Anti-SARS-CoV-2 IgG (Spike) and Anti-SARS-CoV-2 Total (Spike)] and a rapid assay [Medsource Ozone Biomedicals] were evaluated in 100 rRT-PCR diagnosed-recovered frontline HCW with mild disease. Also, seroprevalence was studied in 505 asymptomatic, frontline HCW.
Results: At manufacturers' thresholds, overall sensitivity for Abbott was 71%, Roche 96%, Ortho (both total and IgG(S) 99% and rapid card 56%. Seroprevalence in asymptomatic frontline HCW was found to be 17.6%, with positivity being higher in the HCW group not facing patients directly compared to direct patient caregivers (P = 0.0034).
Conclusion: Assay performance depends on assay design (total IgM & IgG antibodies versus IgG alone), choice of antigen, and time of sample testing from the onset of disease. In our study, Ortho Vitros total-Ab; IgG (Spike), and Roche Elecsys total-Ab (Nucleocapsid) assays were found to have optimal sensitivity. A seroprevalence study in the frontline HCWs at our institute showed that seroprevalence was higher (17.6%) in HCWs in comparison to the community.
- Chemiluminescent assay
- frontline healthcare workers
- SARS-CoV-2 antibody
How to Cite
Epub 2020 Jan.
COVID-19. Coronavirus Pandemic.
Available:https://www.worldometers info/coronavirus/ (last accessed 26th November 2020).
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;ciaa344.
Caruana G, Croxatto A, Coste AT, Opota O, Lamoth F, Jaton K, Greub G. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. Clin Microbiol Infect. 2020;26(9):1178–82.
Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, et.al, Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26(7):1478-1488.
Theel ES, Harring J, Hilgart H, Granger D. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58(8):e01243-20.
ICMR Guidance on rapid antibody test kits for COVID-19
Krüttgen A, Cornelissen CG, Dreher M, Hornef M, Imöhl M, Kleines M. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. J Clin Virol. 2020;128:104394.
FDA EUA Authorized Serology Test Performance.
National SARS-CoV-2 serology assay evaluation group. performance characteristics of five immunoassays for SARS-CoV-2: A head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390-1400.
Epub 2020 Sep 23.
Erratum in: Lancet Infect Dis. 2020 Dec;20(12):e298.
Tan SS, Saw S, Chew KL, Wang C, Pajarillaga A, Khoo C, et al. Comparative clinical evaluation of the roche elecsys and abbott SARS-CoV-2 serology assays for COVID-19. Arch Pathol Lab Med; 2020.
Epub ahead of print.
Chua KYL, Vogrin S, Bittar I, Horvath JH, Wimaleswaran H, Trubiano JA, Holmes NE, Lam Q. Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection. Pathology; 2020.
Mahase Elisabeth. COVID-19: Two antibody tests are “highly specific” but vary in sensitivity, evaluations find BMJ. 2020;369:m2066.
Harritshøj LH, Gybel-Brask M, Afzal S, Kamstrup PR, Jørgensen CS, Thomsen MK, et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol. 2021;59(5):e02596-20.
Loeffelholz MJ. Evaluation of high-throughput serological tests for SARS-CoV-2. J Clin Microbiol. 2020;58(11):e02179-20.
David M Manthei, Jason F Whalen, Lee F Schroeder, Anthony M Sinay, C(ASCP), Shih-Hon Li, Riccardo Valdez, et.al, Differences in performance characteristics among four high-throughput assays for the detection of antibodies against SARS-CoV-2 using a common set of patient samples. American Journal of Clinical Pathology. 2021;155(2):267–279.
Duong YT, Wright CG, Justman J. Antibody testing for coronavirus disease 2019: Not ready for prime time. BMJ. 2020;370:m2655.
Murhekar MV, Bhatnagar T, Selvaraju S, et al, SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: Findings from the second nationwide household serosurvey. Lancet Glob Health. 2021;9(3):e257-e266.
Epub 2021 Jan 27.
Iversen K, Bundgaard H, Hasselbalch R.B, et al. Risk of COVID-19 in health care workers in Denmark: An observational cohort study. The Lancet Infectious Diseases; 2020.
Nakamura A, Sato R, Ando S, et al. Seroprevalence of antibodies to SARS-CoV-2 in health care workers in non-epidemic region: A hospital report in Iwate Prefecture, Japan. medRxiv; 2020.
Nakamura A, Sato R, Ando S, Gómez-Ochoa SA. Franco OH. Rojas LZ, et al. COVID-19 in health care workers: A living systematic review and meta-analysis of prevalence, risk factors, clinical characteristics, and outcomes. Am J Epidemiol; 2020.
Houlihan CF, Vora N, Byrne T, et al. Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health care workers. Lancet. 2020;396:e6-e7.
Rudberg AS, Havervall S, Månberg A, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun 11, 5064; 2020.
Lan FY, Wei CF, Hsu YT, Christiani DC, Kales SN. Work-related COVID-19 transmission in six Asian countries/areas: A follow-up study. PLOS ONE. 2020;15(5):e0233588.
Mahajan NN, Mathe A, Patokar GA, Bahirat S, Lokhande PD, Rakh V, et al. Prevalence and clinical presentation of COVID-19 among healthcare workers at a dedicated hospital in India. J Assoc Physicians India. 2020;68(12):16-21.
Goenka M, Afzalpurkar S, Goenka U, Das SS, Mukherjee M, Jajodia S, et al. Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India. J Assoc Physicians India. 2020;68(11):14-19.
Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLOS ONE. 2021;16(1): e0245556.
Ahnstedt H, McCullough LD. The impact of sex and age on T cell immunity and ischemic stroke outcomes. Cellular Immunology. 2019;345:103960
Abstract View: 174 times
PDF Download: 104 times